The company is targeting cash flow positive status in the second half of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUPH:
- Aurinia Pharmaceuticals submits IND application to FDA for AUR200
- Aurinia Pharmaceuticals put volume heavy and directionally bearish
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia strength may be related to Gilead suspicion, says Gordon Haskett
- Aurinia Pharmaceuticals partner Otsuka files NDA in Japan for Lupkynis
